Turn Therapeutics Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $8.55
- 52-Week Range
- $2.57 – $16.45
- Market Cap
- $271.79M
- P/E (TTM)
- —
- EPS (TTM)
- -0.43
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 47.80
- PEG Ratio
- —
- Return on Equity
- -412.27%
- Return on Assets
- -56.15%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 3.19
- Debt/Equity
- 1.09
- Total Debt
- $6.23M
- Free Cash Flow
- $-2.62M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $267.66M
Market Snapshot
About
Turn Therapeutics is a clinical-stage biotechnology company focused on developing therapies for age-related diseases. The company is working on treatments that target cellular senescence and tissue regeneration to address conditions associated with aging. Turn Therapeutics is advancing a pipeline of novel therapeutics based on its proprietary regenerative medicine platform.